Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177415 | 1.00 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL4182771 | 0.92 | PGR (0.85) | PGRNR3C1NR3C2AR | |
| SCHEMBL6291160 | 0.90 | PGR (0.82) | PGRNR3C1 | |
| SCHEMBL6994720 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL6291626 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL6995370 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL7002320 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL6994556 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL6991539 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR | |
| SCHEMBL6994723 | 0.89 | PGR (0.80) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | PGR 44/4885NR3C1 21/4885NR3C2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.